STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
TBPH THERAVANCE BIOPHARMA INCORPORATED StockScouter® Report
5
StockScouter® Score
THERAVANCE BIOPHARMA INCORPORATED, a small cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year is holding steady compared to earnings growth in the past three years. Neutral
- Shares are neither being accumulated heavily nor sold heavily by financial institutions. Neutral for a small company like TBPH
Concerns
- The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
F
C
F
D